JP2024525843A - マルチアゴニストペプチドを含む組成物並びに製造及び使用方法 - Google Patents

マルチアゴニストペプチドを含む組成物並びに製造及び使用方法 Download PDF

Info

Publication number
JP2024525843A
JP2024525843A JP2024502438A JP2024502438A JP2024525843A JP 2024525843 A JP2024525843 A JP 2024525843A JP 2024502438 A JP2024502438 A JP 2024502438A JP 2024502438 A JP2024502438 A JP 2024502438A JP 2024525843 A JP2024525843 A JP 2024525843A
Authority
JP
Japan
Prior art keywords
peptide
glu
peptides
lys
gip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024502438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525843A5 (cg-RX-API-DMAC7.html
Inventor
マーサ ロンディノーネ,クリスティーナ
エス. ゴーシュ,ソウミトラ
ダンホ,ワリード
Original Assignee
ぺプ2タンゴ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ぺプ2タンゴ セラピューティクス インコーポレイテッド filed Critical ぺプ2タンゴ セラピューティクス インコーポレイテッド
Publication of JP2024525843A publication Critical patent/JP2024525843A/ja
Publication of JP2024525843A5 publication Critical patent/JP2024525843A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024502438A 2021-07-16 2022-07-15 マルチアゴニストペプチドを含む組成物並びに製造及び使用方法 Pending JP2024525843A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163222747P 2021-07-16 2021-07-16
US63/222,747 2021-07-16
PCT/US2022/073793 WO2023288313A1 (en) 2021-07-16 2022-07-15 Compositions including multi-agonist peptides and methods of manufacture and use

Publications (2)

Publication Number Publication Date
JP2024525843A true JP2024525843A (ja) 2024-07-12
JP2024525843A5 JP2024525843A5 (cg-RX-API-DMAC7.html) 2025-07-24

Family

ID=84919777

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502438A Pending JP2024525843A (ja) 2021-07-16 2022-07-15 マルチアゴニストペプチドを含む組成物並びに製造及び使用方法

Country Status (6)

Country Link
US (1) US20230203100A1 (cg-RX-API-DMAC7.html)
EP (1) EP4370537A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024525843A (cg-RX-API-DMAC7.html)
AU (1) AU2022311018A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226003A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023288313A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102966075B1 (ko) * 2024-11-19 2026-05-19 (주)케어젠 항비만 및 항당뇨 활성을 갖는 펩타이드 및 이의 용도

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240059753A1 (en) * 2022-07-15 2024-02-22 Pep2Tango Therapeutics Inc. Compositions including multi-agonist peptides and methods of manufacture and use
AU2024218747A1 (en) * 2023-02-10 2025-08-28 Hangzhou Sciwind Biosciences Co., Ltd. Polypeptide and derivative thereof, composition, and use thereof
TWI926512B (zh) * 2023-11-30 2026-05-21 丹麥商諾佛 儂迪克股份有限公司 Glp-1、gip及澱粉素受體之三重促效劑
US20250236656A1 (en) * 2023-12-12 2025-07-24 Amide Technologies Multimeric polypeptides and uses thereof
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
KR102991397B1 (ko) 2024-11-29 2026-07-21 노보 노르디스크 에이/에스 Glp-1, gip, 및 아밀린 수용체의 삼중작용제 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042922A2 (en) * 2007-09-27 2009-04-02 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2597649A1 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
SI2864350T1 (en) * 2012-06-21 2018-08-31 Indiana University Research And Technology Corporation GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR
EP3856768A2 (en) * 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
IL296219A (en) * 2020-03-25 2022-11-01 Takeda Pharmaceuticals Co Qw dosing of gip receptor agonist peptide compounds and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042922A2 (en) * 2007-09-27 2009-04-02 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102966075B1 (ko) * 2024-11-19 2026-05-19 (주)케어젠 항비만 및 항당뇨 활성을 갖는 펩타이드 및 이의 용도

Also Published As

Publication number Publication date
WO2023288313A1 (en) 2023-01-19
CA3226003A1 (en) 2023-01-19
US20230203100A1 (en) 2023-06-29
EP4370537A4 (en) 2025-05-14
EP4370537A1 (en) 2024-05-22
AU2022311018A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
JP7541600B2 (ja) Gipアゴニスト化合物及び方法
US20230203100A1 (en) Compositions including multi-agonist peptides and methods of manufacture and use
US11008375B2 (en) GIP-GLP-1 dual agonist compounds and methods
US20240059753A1 (en) Compositions including multi-agonist peptides and methods of manufacture and use
US8895498B2 (en) GIP and exendin hybrid polypeptides
EP2057188B1 (en) Dpp-iv resistant gip hybrid polypeptides with selectable properties
US8497240B2 (en) DPP-IV resistant GIP hybrid polypeptides with selectable properties
CN104837864A (zh) 作为glp1/胰高血糖素双重激动剂的毒蜥外泌肽-4衍生物
CN104870009A (zh) 官能化的毒蜥外泌肽-4衍生物
AU2006213607A1 (en) GIP analog and hybrid polypeptides with selectable properties
HK40069710A (en) Gip agonist compounds and methods
HK1242216A1 (en) Gip agonist compounds and methods
HK1242216B (en) Gip agonist compounds and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260807